Addition of vandetanib to pegylated liposomal doxorubicin...

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

Harter, Philipp, Sehouli, Jalid, Kimmig, Rainer, Rau, Jörn, Hilpert, Felix, Kurzeder, Christian, Elser, Gabriele, Bois, Andreas
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-013-0011-3
Date:
December, 2013
File:
PDF, 162 KB
english, 2013
Conversion to is in progress
Conversion to is failed